Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Tyrosine Kinase Inhibitor Discontinuation in Patients With Chronic Myeloid Leukemia

Tyrosine Kinase Inhibitor Discontinuation in Patients With Chronic Myeloid Leukemia Tyrosine Kinase Inhibitor Discontinuation in Patients With Chronic Myeloid Leukemia Invited Commentary Invited Commentary Tyrosine Kinase Inhibitor Discontinuation in Patients With Chronic Myeloid Leukemia Updates From the LAST Study on Patient-Reported Outcomes and Biomarkers for Relapse Theodore P. Braun, MD, PhD; Brian J. Druker, MD More than 20 years ago, the first patients were enrolled in a median follow-up of 42 months, approximately 60% of pa- the phase 1 trial of imatinib for treatment of chronic myeloid tients remained in TFR after treatment discontinuation. leukemia (CML). Inhibiting the kinase activity of the BCR- Patient-reported outcomes were assessed 12 months ABL1 fusion protein, the driving molecular abnormality of after discontinuation and showed that patients in TFR had this disease, has rendered clinically meaningful improvements in fatigue, depression, this once deadly leukemia a gastrointestinal upset, sleep, and pain. While not unsurpris- Related article manageable condition. For ing, these findings are consequential. Although there is no patients with CML, a good disease outcome with nearly nor- doubt that the currently available ABL TKIs cause many mal lifespan is expected, but treatment adverse effects objectively assessed adverse effects, such as fluid retention, remain a significant issue. While adverse effect profiles pleural effusions, and http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Tyrosine Kinase Inhibitor Discontinuation in Patients With Chronic Myeloid Leukemia

JAMA Oncology , Volume 7 (1) – Jan 12, 2021

Loading next page...
 
/lp/american-medical-association/tyrosine-kinase-inhibitor-discontinuation-in-patients-with-chronic-dkd0GlvFWI
Publisher
American Medical Association
Copyright
Copyright 2020 American Medical Association. All Rights Reserved.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2020.5772
Publisher site
See Article on Publisher Site

Abstract

Tyrosine Kinase Inhibitor Discontinuation in Patients With Chronic Myeloid Leukemia Invited Commentary Invited Commentary Tyrosine Kinase Inhibitor Discontinuation in Patients With Chronic Myeloid Leukemia Updates From the LAST Study on Patient-Reported Outcomes and Biomarkers for Relapse Theodore P. Braun, MD, PhD; Brian J. Druker, MD More than 20 years ago, the first patients were enrolled in a median follow-up of 42 months, approximately 60% of pa- the phase 1 trial of imatinib for treatment of chronic myeloid tients remained in TFR after treatment discontinuation. leukemia (CML). Inhibiting the kinase activity of the BCR- Patient-reported outcomes were assessed 12 months ABL1 fusion protein, the driving molecular abnormality of after discontinuation and showed that patients in TFR had this disease, has rendered clinically meaningful improvements in fatigue, depression, this once deadly leukemia a gastrointestinal upset, sleep, and pain. While not unsurpris- Related article manageable condition. For ing, these findings are consequential. Although there is no patients with CML, a good disease outcome with nearly nor- doubt that the currently available ABL TKIs cause many mal lifespan is expected, but treatment adverse effects objectively assessed adverse effects, such as fluid retention, remain a significant issue. While adverse effect profiles pleural effusions, and

Journal

JAMA OncologyAmerican Medical Association

Published: Jan 12, 2021

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$499/year

Save searches from
Google Scholar,
PubMed

Create folders to
organize your research

Export folders, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month